SCHEMBL1361268

SCHEMBL1361268

Cc1ccccc1N1CCC(=O)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.58
ALDH1A1 P00352 1/20 0.52
HPGD P15428 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ALOX5 P09917 2/20 0.51
LMNA P02545 1/20 0.51
MCOLN3 Q8TDD5 1/20 0.51
ADRA1B P35368 2/20 0.51
ADRA1D P25100 1/20 0.51
ADRA1A P35348 1/20 0.51
DDB1 Q16531 1/20 0.50
CRBN Q96SW2 1/20 0.50
AKR1C3 P42330 1/20 0.49
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
MGLL Q99685 1/20 0.47
TSHR P16473 1/20 0.46
HTR7 P34969 1/20 0.46
AR P10275 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9831929 0.89 ALDH1A1 (0.53) ADRB1ALDH1A1HPGDSMN1; SMN2ALOX5
SCHEMBL28041973 0.85 ADRB1 (0.61) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL4291189 0.83 ADRB1 (0.72) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL14117680 0.79 FAAH (0.51) ALDH1A1MAPTMGLLHTR7
SCHEMBL3436625 0.79 ADRB1 (0.62) ADRB1ALDH1A1HPGDSMN1; SMN2ALOX5
SCHEMBL329301 0.79 ADRB1 (0.67) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL27961590 0.79 ADRB1 (0.67) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL11089710 0.78 LMNA (0.58) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL486689 0.78 ALOX5 (0.50) ALDH1A1ALOX5LMNAMEN1MAPT
Hydrochloric Acid SCHEMBL486707 0.77 ALOX5 (0.49) ALDH1A1ALOX5LMNAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112243439-A Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof 百济神州有限公司 2021-01-19 CN disclosed
WO-2019238067-A1 PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF BEIGENE, LTD. (KY) 2019-12-19 WO disclosed
WO-2019022223-A1 CYCLIC AMINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES 東レ株式会社 2019-01-31 WO disclosed
US-20120214807-A1 COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-08-23 US disclosed
US-8067457-B2 Compounds useful as antagonists of CCR2 MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100190824-A1 Novel Substituted Piperidones as HSP Inducers TORRENT PHARMACEUTICALS LTD. (IN) 2010-07-29 US disclosed
CN-101790516-A Novel substituted piperidones as hsp inducers TORRENT PHARMACEUTICALS LTD 2010-07-28 CN disclosed
WO-2010081851-A1 PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION GENOSCIENCE PHARMA (FR) 2010-07-22 WO disclosed
US-20090197884-A1 Compounds Useful as Antagonists of CCR2 MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-08-06 US disclosed
US-20080177036-A1 Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity CHEN LI 2008-07-24 US disclosed
US-20080177036-A1 Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity CHEN LI 2008-07-24 US disclosed
EP-1272516-B1 SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY HOFFMANN LA ROCHE (CH) 2008-04-23 EP disclosed
WO-2007053498-A1 COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-05-10 WO disclosed
US-6376503-B1 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA MERCK & CO., INC 2002-04-23 US disclosed
EP-1023068-A4 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2001-05-16 EP disclosed
EP-1023068-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-08-02 EP disclosed
WO-1998057638-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080177036-A1 Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity MC4R, MC3R, MC1R ADRB1 222/4885ALDH1A1 4730/4885HPGD 3939/4885
US-20120214807-A1 COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 CCR2, CCR1, CXCR3 ADRB1 116/4885ALDH1A1 1292/4885HPGD 1479/4885
US-20090197884-A1 Compounds Useful as Antagonists of CCR2 CCR2, CCR1, CXCR3 ADRB1 116/4885ALDH1A1 1292/4885HPGD 1479/4885
US-20100190824-A1 Novel Substituted Piperidones as HSP Inducers HSF1, HSPA4, HSPA5 ADRB1 174/4885ALDH1A1 541/4885HPGD 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.